COURT SUSTAINS PATENT ON LILLY SCHIZOPHRENIA DRUG Eli Lilly & Co. v. Zenith Goldline Pharms. | Secondary Sources | Westlaw

COURT SUSTAINS PATENT ON LILLY SCHIZOPHRENIA DRUG Eli Lilly & Co. v. Zenith Goldline Pharms. | Secondary Sources | Westlaw

View on Westlaw or start a FREE TRIAL today, COURT SUSTAINS PATENT ON LILLY SCHIZOPHRENIA DRUG Eli Lilly & Co. v. Zenith Goldline Pharms., Secondary Sources
Skip Page Header

COURT SUSTAINS PATENT ON LILLY SCHIZOPHRENIA DRUG Eli Lilly & Co. v. Zenith Goldline Pharms.

12 No. 1 ANIPLR 5Andrews Intellectual Property Litigation Reporter (Approx. 4 pages)

COURT SUSTAINS PATENT ON LILLY SCHIZOPHRENIA DRUG Eli Lilly & Co. v. Zenith Goldline Pharms.

12 No. 1 ANIPLR 5Andrews Intellectual Property Litigation Reporter (Approx. 4 pages)

12 No. 1 Andrews Intell. Prop. Litig. Rep. 5
Andrews Intellectual Property Litigation Reporter
*1 April 26, 2005
Patent Infringement
Copyright © 2005 Thomson/West .

COURT SUSTAINS PATENT ON LILLY SCHIZOPHRENIA DRUG

Eli Lilly & Co. v. Zenith Goldline Pharms.

A federal judge in Indianapolis has rejected an attempt by three generic drug manufacturers to invalidate Eli Lilly & Co.'s patent on the popular antipsychotic drug, Zyprexa. The ruling bars their attempt to market a generic version of the drug...
End of Document© 2023 Thomson Reuters. No claim to original U.S. Government Works.